肺炎球菌结合疫苗接种的效果与成本效益:全球建模分析
该全球建模研究整合生态模型与决策树模型,评估180个国家2015至2045年30个出生队列接种13价肺炎球菌结合疫苗(PCV13)的效果与成本效益。
要点
- PCV13使用在全部六个联合国区域可能具有成本效益。
- Gavi支持资格的71国占可预防死亡的83%但仅占全球接种成本的18%。
核心结论
- 全球PCV13接种可显著减少儿童死亡与疾病发作,且在所有六个联合国区域可能具有成本效益。
- 研究结果支持Gavi对低收入国家引入PCV的支持,以及提高非Gavi支持或过渡国家PCV可负担性的努力。
研究设计与样本
- 整合生态模型(用13个高收入地区七价PCV接种后数据验证的简约机制模型)预测PCV对儿童侵袭性肺炎球菌病的影响。
- 整合决策树模型预测接种与不接种策略下的临床表现为与经济学结局。
- 模型随访180个国家2015至2045年30个出生队列至5岁,并进行单因素情景与概率敏感性分析。
主要发现
- PCV13使用在全部六个联合国区域可能具有成本效益。
- Gavi支持资格的71国占PCV13可预防死亡的83%但仅占全球接种成本的18%。
临床怎么用
- 为预防医学与公共卫生决策者提供PCV13全球引入的成本效益证据,支持在低收入国家推进接种。
- 提示应关注非Gavi支持或过渡国家的PCV可负担性问题。
- 可用于评估不同区域PCV13接种的公共卫生价值与资源分配。
局限性
- 模型预测基于生态模型与决策树模型的整合,存在模型不确定性,已通过单因素情景与概率敏感性分析探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Introduction of pneumococcal conjugate vaccines (PCVs) has substantially reduced disease burden due to Streptococcus pneumoniae, a leading cause of childhood morbidity and mortality globally. However, PCVs are among the most expensive vaccines, hindering their introduction in some settings and threatening sustainability in others. We aimed to assess the effect and cost-effectiveness of introduction of 13-valent PCV (PCV13) vaccination globally. METHODS: We assessed the incremental cost-effectiveness ratio of PCV13 introduction by integrating two models: an ecological model (a parsimonious, mechanistic model validated with data from post-seven-valent PCV introduction in 13 high-income settings) to predict the effect of PCV on childhood invasive pneumococcal disease, and a decision-tree model to predict a range of clinical presentations and economic outcomes under vaccination and no-vaccination strategies. The models followed 30 birth cohorts up to age 5 years in 180 countries from 2015 to 2045. One-way scenario and probabilistic sensitivity analyses were done to explore model uncertainties. FINDINGS: We estimate that global PCV13 use could prevent 0·399 million child deaths (95% credible interval 0·208 million to 0·711 million) and 54·6 million disease episodes (51·8 million to 58·1 million) annually. Global vaccine costs (in 2015 international dollars) of $15·5 billion could be partially offset by health-care savings of $3·19 billion (2·62 billion to 3·92 billion) and societal cost savings of $2·64 billion (2·13 billion to 3·28 billion). PCV13 use is probably cost-effective in all six UN regions. The 71 countries eligible for support from Gavi, the Vaccine Alliance, account for 83% of PCV13-preventable deaths but only 18% of global vaccination costs. The expected cost of PCV vaccination globally is around $16 billion per year. INTERPRETATION: Our findings highlight the value of Gavi's support for PCV introduction in low-income countries and of efforts to improve the affordability of PCVs in countries not eligible for, or transitioning from, Gavi support. FUNDING: World Health Organization; Gavi, the Vaccine Alliance; and the Bill & Melinda Gates Foundation.
引用
- Chen C, Cervero Liceras F, Flasche S, et al. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Glob Health. 2019. PMID: 30554762. doi:10.1016/S2214-109X(18)30422-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。